What is technology transfer and when do you need it?
Technology transfer is the structured move of a manufacturing process and its analytical methods from a sending unit to a receiving unit, so the receiving site can make the same drug substance or drug product, to the same specification, with the same control strategy. It is not just shipping a batch record and wishing the new site luck. A real transfer carries the process description, the analytical methods, the raw-material and component specifications, the in-process controls, the critical process parameters, and the knowledge a senior process scientist holds in their head about what actually goes wrong on the floor. The output is a receiving site that runs the process under its own quality system and produces material that is demonstrably comparable to what the sending site made.
Sponsors hit technology transfer at a handful of predictable moments. You scale up from development or pilot to a clinical or commercial CDMO. You switch CDMOs because of capacity, cost, quality findings, or a relationship that soured. You qualify a second source so a single-site failure does not halt your supply. You move a process in-house, or out of house. And you transfer analytical methods between QC labs, which is its own workstream and often the part that slips. Each of these is a transfer, and each carries the same core risk: the new site does not reproduce the old site's performance on the first attempt, and you find out late.
Why it deserves its own attention is comparability. A regulator does not care that two sites followed the same paper. They care that the product is the same. That means head-to-head analytical comparison, sometimes side-by-side or split-batch runs, and a defensible comparability protocol agreed before the receiving site makes registration-relevant material. For biologics, viral vector, mRNA, and cell therapy, where the process defines the product, comparability is harder and the bar is higher than for a small-molecule API. Get the transfer plan and the comparability strategy right up front and the rest is execution. Get them wrong and you are repeating GMP batches at six figures each.
What does a technology transfer CRO or CDMO actually do?
Most technology transfer work is run by the receiving CDMO, sometimes supported by a CRO or consultant who owns the analytical method transfer or the program management across both sites. The scope splits into process transfer and analytical method transfer, and the two run on linked but separate tracks. Underestimating the analytical side is the classic mistake: you cannot release a batch with a method the receiving QC lab has not yet qualified, so method transfer often gates the whole timeline.
On the process side, the vendor takes in the process description and the development or manufacturing history, performs a gap assessment against its own equipment and facility, adapts the process to the receiving site's trains and scale, runs engineering or demonstration batches to confirm the process behaves, and then executes the GMP runs that produce usable material. On the analytical side, methods (identity, purity, potency, residuals, and the rest of the release and stability panel) are transferred and qualified at the receiving lab, usually through comparative testing or co-validation so the new lab demonstrably reproduces the original results. Underneath both sits the documentation a transfer lives or dies on: the transfer plan, the gap assessment, the risk assessment, the comparability protocol, and the final transfer report.
- Transfer planning and gap assessment: a transfer protocol, a facility and equipment fit-gap against the receiving site, and a risk assessment of which steps are most likely to behave differently at the new site.
- Process transfer and scale-up: adapting upstream and downstream unit operations to the receiving site, scale-up or scale-down, and engineering or demonstration runs before the GMP campaign.
- Analytical method transfer: transferring and qualifying release and stability methods at the receiving QC lab through comparative testing or co-validation, including method-suitability and acceptance criteria.
- Comparability: a comparability protocol, side-by-side or split-batch testing where needed, and the analytical package that shows the receiving site's material matches the sending site's.
- Documentation and regulatory support: the transfer report, updated batch records and specifications, and the change control or post-approval supplement (CBE-30, PAS, or the regional equivalent) the transfer triggers.
How do you choose a technology transfer CRO or CDMO?
The receiving site you choose is, in practice, your long-term manufacturer, so this is a higher-stakes pick than a one-off study. Score two or three candidates against the same written transfer scope rather than collecting quotes that measure different things. The fastest filter is whether the site runs your modality and your process type routinely, because a transfer into a site that has done this exact kind of process many times is a different risk than a transfer into a site that is learning it on your dollar. Below the headline price, weigh how many comparable transfers the team has actually completed and how many of those products went on to clear a regulatory review.
- Quality and GMP status: confirm the GMP grade you need (or non-GMP for a development-stage transfer), the inspection history, and which agencies (FDA, EMA, PMDA) have audited the receiving site, since that track record is what lets you cite the work in a filing.
- Capacity and lead time: real slot availability and a realistic timeline (gap assessment, engineering runs, GMP campaign, method qualification, comparability), plus an honest answer on what historically causes transfer slippage. Good sites book out well ahead.
- Modality and indication fit: a vendor that runs your process type weekly, whether that is a CHO-expressed antibody, an AAV vector, an mRNA-LNP product, a cell therapy, an ADC, or a small-molecule API, not a generalist stretching to win the work.
- Region and regulatory track record: where the receiving site sits relative to where you plan to file and supply, and a documented history of supporting transfers and post-approval changes in those markets.
- Data quality and comparability rigor: a clear comparability strategy, sound analytical method transfer practice, and transparent reporting of any out-of-trend or out-of-spec results during demonstration runs, not just the clean ones.
- IP and confidentiality: how your process knowledge, cell bank, methods, and data are protected, who owns process improvements made during the transfer, and clean terms on material and data handling before any package changes hands.